Login to Your Account

Other News To Note

Thursday, March 14, 2013

• Oxford Gene Technology, of Oxford, UK, was granted a license by the Institute of Cancer Research, London, to further develop and commercialize a new panel of diagnostic and prognostic microRNA biomarkers for prostate cancer. Terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription